Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Breaking News

Wall Street Journal Pharmalot: FDA Leans on Another Compound Pharmacy for Manufacturing Problems

Thursday, March 12, 2015   (0 Comments)
Posted by: Dagmar Anderson
Share |

IACP weighs in on today's Wall Street Journal Pharmalot article by Ed Silverman: "FDA Leans on Another Compound Pharmacy for Manufacturing Problems."


A spokesman for the International Academy of Compounding Pharmacists (IACP), a trade group, expressed concern about the string of consent decrees. “The consent decree is a necessary enforcement tool for the FDA and we do not object to its use. A consent decree can serve as a basis for the government and a pharmacy to agree on steps that must be taken to assure safety and resume production,” he says.

“What does concern IACP is the way these agreements, when reached with compounding pharmacies, are publicized because it appears they are publicized by FDA much more broadly than enforcement actions involving drug makers,” he continues. “They seem intent on raising broad public concern about compounding, rather than on informing the public about one particular pharmacy or agreement.”


Click here to read the WSJ article.

Association Management Software Powered by YourMembership  ::  Legal